SCHEMBL10150585

SCHEMBL10150585

C=CC[C@@H](OC(=O)c1c(C)cc(C)cc1C)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.43
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 3/20 0.39
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
OPRD1 P41143 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HCAR2 Q8TDS4 1/20 0.35
UTS2R Q9UKP6 1/20 0.34
CRHR1 P34998 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150586 0.86 KMT2A (0.42) LMNAGAAALDH1A1SLC6A2SLC6A4
SCHEMBL10150601 0.84 CYP2C19 (0.39) CYP2C19PPARGPPARALMNAGAA
SCHEMBL10150602 0.84 CYP2C19 (0.39) CYP2C19PPARGPPARALMNAGAA
SCHEMBL10150631 0.82 PPARG (0.36) CYP2C19PPARGPPARALMNAGAA
SCHEMBL10150632 0.82 PPARG (0.36) CYP2C19PPARGPPARALMNAGAA
SCHEMBL10150584 0.81 ALDH1A1 (0.38) CYP2C19ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL10150589 0.80 THRB (0.37) CYP2C19PPARGPPARAOPRD1MEN1
SCHEMBL28435120 0.79 CYP2C19 (0.51) CYP2C19PPARGPPARALMNAALDH1A1
SCHEMBL10150593 0.77 CRHR1 (0.36) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL12142624 0.77 CRHR1 (0.36) LMNAGAAALDH1A1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P CYP2C19 2805/4885PPARG 2706/4885PPARA 3536/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 CYP2C19 4183/4885PPARG 3497/4885PPARA 3688/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P CYP2C19 2805/4885PPARG 2706/4885PPARA 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.